[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cvd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cvd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,83,106,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100560671","theoretically-informed-behavioral-intervention-100560671",false,"NCT06580184","Theoretically Informed Behavioral Intervention","Theoretically Informed Behavioral Intervention to Prevent HIV-related Comorbidities","Inclusion Criteria:\n\nSelf-identify as:\n\n* living with HIV\n* English speaking\n* Access to a device compatible with LEARN 2\n\nExclusion Criteria:\n\n\\- medical history of serious complications such as heart attack, stroke, cognitive impairment, or cancer.","MALE","18 Years",{"count":19,"type":20},164,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this waitlist control clinical trial is to learn if the tailored LEARN 2 platform can prevent HIV-related comorbidities with shared risk factors in men ages 18 and older living with HIV. The main question\\[s\\] are:\n\n1. Can the virtual environment improve quality of life among these participants?\n2. Does the LEARN 2 platform effectively serve as prevention education for HIV comorbidity shared risk factors?\n\nResearchers will compare participants receiving the LEARN2 virtual environment intervention to those in a waitlist control group to see if the intervention leads to improvements in quality of life and reductions in risk factors.\n\nParticipants will be asked to:\n\n1. Engage with the virtual environment weekly.\n2. Participate in virtual live health educator sessions.\n3. Complete daily assessments of personal health behaviors through Ecological Momentary Assessment.",[26,27,28],"HIV","CVD","Metabolic Disease",[30,26,27,31,32,33,34,35],"Syndemic","HTN","Diabetes Mellitus","Cancer","Virtual Reality","Prevention","NOT_YET_RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":20},"2026-10",{"date":44,"type":20},"2029-03-31",{"name":46,"class":47},"Yale University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100636821","global-longitudinal-health-monitoring-and-blood-sample-collection-study-to-promote-early-stage-disease-detection-and-personalizedprecision-care-using-innovative-research-platforms-100636821","NCT07570667","Global Longitudinal Health Monitoring and Blood Sample Collection Study to Promote Early-stage Disease Detection and Personalized\u002FPrecision Care Using Innovative Research Platforms","Inclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Male or female participants.\n3. Age at Visit 1: 40 years - 70 years.\n4. For Low-risk Arm: Assessed as healthy (free of acute or chronic disease) with no cardiovascular risk conditions listed in Inclusion criteria 5. Participants may have mild disorders that do not require regular therapeutic (pharmacological) intervention; For High-risk Arm: Assessed as healthy (free of acute or chronic diseases) with cardiovascular risk conditions listed in Inclusion criteria 5. Participant may have mild disorders that do not require regular therapeutic (pharmacological) intervention.\n5. For Low-risk Arm: Has low risk to contract an NCD in the upcoming years, according to the following criteria: a) Non-hypertensive person according to criteria of the relevant national guideline, who never received antihypertensive medication; b) Total cholesterol: \\\u003C 5.2 mmol\u002FL (\\\u003C200 mg\u002FdL) with no history of lipid-lowering (e.g., statin) treatment; c) Non smoker or with no significant smoking history (\\\u003C5 pack-years); For High-risk Arm: Has high risk to contract an NCD in the upcoming years, confirmed by the presence of at least 2 out of the following 3 criteria (a, b, c): a) Medically controlled hypertension: participants with diagnosed hypertension receiving antihypertensive medication ; b) Medically controlled dyslipidemia or hypercholesterolemia: participants with diagnosed dyslipidemia or hypercholesterolemia receiving lipid-lowering medication; c) Significant smoking history (tobacco exposure of \\>20 pack-years) and\u002For 1st degree family member with history of lung cancer.\n6. BMI: 18.5 - 35.0 kg\u002Fm\\^2.\n7. Willingness to fill in the study questionnaire.\n8. Willingness to participate in future visits and medical investigations as defined per protocol.\n9. Willingness to be followed-up on disease outcome through data linkage to the participant's health-related records.\n\nExclusion Criteria:\n\n1. Pregnancy at Visit 1 (self-reported, no test required).\n2. For low-risk arm: Past medical history (PMH) of target NCDs, any other significant health conditions, clinical symptoms, abnormalities of blood parameters or medical tests suggesting the presence of abnormal health conditions at Visit 1. Any condition that is inadequately controlled. The sponsor should be contacted for advice in case of any uncertainties; For high-risk arm: Except for the conditions mentioned under inclusion criteria (point 5a and b), participants with PMH of target NCDs, any other health conditions, clinical symptoms, abnormalities of blood parameters or medical tests suggesting the presence of abnormal health conditions at Visit 1 are excluded from the study. Any condition that is inadequately controlled. Sponsor should be contacted for advice in case of any uncertainties.\n3. For low-risk arm: Any chronic, systemic drug therapy at Visit 1 (prescription); For high-risk arm: Any chronic, systemic drug therapy at Visit 1 except for conditions mentioned under Inclusion criteria (point 5a and b).\n4. History of HIV, HBV, HCV or HEV infection at Visit 1.\n5. Vulnerable participants.\n6. Foreseeable lack of compliance.",true,"ALL","40 Years","70 Years",{"count":60,"type":20},15000,"OBSERVATIONAL","The investigators propose a prospective, longitudinal, observational study to improve health assessment by analyzing blood plasma molecular patterns in each individual over time using artificial intelligence (AI) to identify key measurements for early detection of NCDs. It will develop personalized reference ranges and screening methods, laying the foundation for population-based early detection. This study focus on collecting health data and biospecimen samples to understand early molecular changes linked to disease.",[27,64,65,33,66],"Type 2 Diabetes","COPD","Hypertension",[68,69,70,71,72,73],"Personalized health","Molecular fingerprints","Longitudinal health monitoring","early-stage disease detection","innovative research platforms","Precision care","2026-04-29",{"date":76,"type":40},"2026-05-06",{"date":78,"type":20},"2026-05-01",{"date":80,"type":20},"2048-05-29",{"name":82,"class":47},"The University of Hong Kong",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":55,"sex":56,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":48},"100536284","heartwise---p-cardiac-for-chinese-population-based-study-100536284","NCT06262828","HEARTWISE - P-CARDIAC for Chinese: Population-based Study","Harnessing Evidence And Real-world Data To Improve Cardiovascular Health and Services (HEARTWISE) - The Personalised - CARdiovascular DIsease Risk Assessment for Chinese (P-CARDIAC) Real World Evidence Study - Population-based Study","HEARTWISE","Inclusion Criteria:\n\n* Individuals aged 18 - 80 years old who visit the medical or cardiology SOPC clinics at the Queen Mary Hospital (QMH), Pok Oi Hospital (POH), Kwong Wah Hospital (KWH), Princess Margaret Hospital (PMH), Queen Elizabeth Hospital (QEH), Tuen Mun Hospital (TMH) and experienced prior CVD event (such as peripheral artery diseases, coronary heart diseases, myocardial infarction, stroke, revascularization) before the scheduled SOPC clinic visit date are eligible to participate in this study. Participants will be also able to comprehend English or Traditional Chinese as well.\n\nExclusion Criteria:\n\n* People with history of dementia, psychiatric diseases or physical impairment.","80 Years",{"count":93,"type":20},3800,"Cardiovascular disease (CVD) is one of the prominent diseases that affect many people. One cost-effective solution is to identify people at higher risk of CVD by CVD risk prediction model. China-PAR, TRS-2P, and SMART2 are common risk prediction models for prevention. However, these risk scores were mostly based on the routinely self-check health information and multivariable regression without time-varying consideration. Investigators developed a Machine Learning (ML) based risk prediction model, Personalized CARdiovascular DIsease risk Assessment for Chinese (P-CARDIAC) among a predominantly Chinese population in Hong Kong to estimates the 10 years of secondary recurrent CVD risk for the high-risk individuals. The study objective is to evaluate the accuracy of the P-CARDIAC performance in practice among a large-scale Hong Kong population in medicine specialist outpatient clinic (SOPC) and cardiac clinic. The results will reassure cardiologists that the P-CARDIAC risk score is sensitive to the heart disease symptoms. Investigators anticipate that the results may help to facilitate P-CARDIAC in clinical setting and provide more practical information with the development of P-CARDIAC.",[96,27],"Cardiovascular Diseases","RECRUITING","2024-10-21",{"date":100,"type":40},"2024-10-24",{"date":102,"type":40},"2024-04-25",{"date":104,"type":20},"2028-04-30",{"name":82,"class":47},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":55,"sex":56,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100494321","eegmecgemg-evaluating-the-severity-of-aortic-stenosis-heart-failure-and-ischemic-stroke-through-an-artificial-intelligenceassisted-system-100494321","NCT05716659","EEG\u002FMECG\u002FEMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.","Assessment of Brain-heart-muscle Axis Using EEG\u002FMECG\u002FEMG Combo Machine for Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.","Inclusion criteria\n\n1. Age≥20 year-old\n2. Healthy subjects or patients with A. Metabolic syndrome (MetS) ；B. HF with reduced ejection fractions (HFrEF, defined by left ventricular ejection fraction≤40%) and current or previous symptoms of HF；C. Severe aortic stenosis (defined aortic valve area \\\u003C 1.0 cm2 or mean pressure gradient ≥ 40 mmHg), preparing to receive transcatheter aortic valve replacement ；D. Acute ischemic stroke and admitted to stroke intensive care unit (ICU), within 24 hours after onset\n\nThe criteria of MetS includes:\n\n1. Abdominal obesity: waist circumference (for Asians) ≥ 90 cm in men and ≥ 80 cm in women;\n2. Hyperglycemia: serum fasting glucose level ≥ 100 mg\u002Fdl, or receiving drug treatment for elevated blood sugar;\n3. Reduced high-density lipoprotein cholesterol (HDL-C): serum HDL-C \\\u003C 40 mg\u002Fdl in men and \\\u003C 50 mg\u002Fdl in women or on cholesterol drug treatment;\n4. Elevated triglycerides: serum triglyceride ≥ 150 mg\u002Fdl or on drug treatment of hypertriglyceridemia;\n5. Hypertension: systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, or on antihypertensive drug treatment.\n\nExclusion criteria:\n\n1. Under treatment for malignancy\n2. Currently receiving immunosuppressants\n3. Modified Rankin Scale (mRS) ≥2 prior to the stroke\n4. Symptomatic HF in patients with acute ischemic stroke\n5. Unable to perform neurocognitive function test\n6. Unable to evaluate the physical activity using questionnaire or 6-minute walk test\n7. Unable to cooperate with examinations using 3E combo machine.","20 Years",{"count":115,"type":20},750,"The specific objectives and methods of this project are: (1) To test the feasibility and accuracy of integrating EEG, MECG and EMG for detecting the severity of diseases such as aortic stenosis, heart failure and ischemic stroke. (2) Improve the accuracy of this multi-channel brain-heart-muscle device by using an artificial intelligence auxiliary system. (3) Provide tailor-made interdisciplinary treatment strategies for patients with different disease states.",[27],[119,120,121],"heart failure","aortic stenosis","ischemic stroke","2023-04-06",{"date":124,"type":40},"2023-04-10",{"date":126,"type":20},"2023-05-30",{"date":128,"type":20},"2032-08-31",{"name":130,"class":47},"National Taiwan University Hospital",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":56,"minAge":113,"maxAge":138,"enrollmentInfo":4,"targetDuration":4,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":153,"locationsCount":4},"100130329","a-multicenter-randomized-parallel-group-study-to-investigate-the-efficacy-of-a-combination-of-rosuvastatin-and-fenofibrate-in-the-patients-with-diabetes-or-atherosclerotic-vascular-diseases-with-metabolic-syndrome-100130329","NCT00965315","A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome","A Multicenter, Randomized, Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome","* Men or women aged 20-79 years\n* with definite DM or atherosclerotic vascular diseases with metabolic syndrome (defined as the presence of three or more of the following risk factors:\n\n  * abdominal obesity \\[waist circumference \\> 90 cm in men or \\> 80 cm in women\\],\n* triglycerides \\> 150 mg\u002FdL, HDL-cholesterol \\\u003C 40 mg\u002FdL in men or \\\u003C 50 mg\u002FdL in women, blood pressure \\> 130\u002F85 mm Hg,\n* or fasting glucose \\> 100 mg\u002FdL) and who are qualified for lipid lowering therapy according to the Taiwanese national guidelines (LDL-C 130-190 mg\u002FdL or TG 200-500 mg\u002FdL with HDL-C \\\u003C 40 mg\u002FdL or TC\u002FHDL-C \\> 5) will be eligible. The main exclusion criteria will be any known contraindications to statin or fibrate therapy,\n* previous intolerance to statin or fibrate in low or high doses,\n* liver enzyme levels more than 3 times the upper limit of normal,\n* pregnancy or breastfeeding,\n* nephrotic syndrome,\n* uncontrolled diabetes mellitus (HbA1c \\> 9),\n* uncontrolled hypothyroidism,\n* plasma LDL-C level higher than 190 mg\u002FdL or triglyceride level higher than 500 mg\u002FdL,\n* coronary heart disease event or revascularisation within a month, congestive heart failure (New York Heart Association classification IIIb or IV),\n* hemodynamically important valvular heart disease, gastrointestinal conditions affecting absorption of drugs,\n* treatment with other drugs that seriously affect the pharmacokinetics of statins or fibrate,\n* unexplained creatine phosphokinase concentrations six or more times the upper limit of normal,\n* life-threatening malignancy,\n* treatment with immuno suppressive or other lipid lowering drugs.\n* Patients previously treated with monotherapy with statins or fibrates will be qualified if they have not already had titration to a dose higher than the equivalent of 5 mg\u002Fd of rosuvastatin or 80 mg\u002Fd of SFC fenofibrate.","79 Years","EXPANDED_ACCESS","Diabetic patients have an excess risk of mortality due to cardiovascular diseases (CVD) compared to non-diabetics. Cardiovascular disease mortality rate is reportedly on the rise in several countries in the region, including urban China, Malaysia, Korea and Taiwan. Cardiovascular diseases and stroke are always the number 2 and 3 killers for Taiwanese population in recent years, and they really cost much from our medical resource. For treating dyslipidemia, one of the major risk factor for CVD, statins have been well documented to reduce CV deaths both for primary and secondary prevention in several large-scale trials. It has been reported that the clinical benefits of treating dyslipidemia in patients with diabetes mellitus should be at least equivalent to the benefits observed among those with cardiovascular disease. A meta-analysis of seven trials of statins found that treatment for about 5 years resulted in a 25% reduction in the combined outcome of coronary heart disease death and non-fatal myocardial infarction. Fibrates are another group of hypolipidemic drugs that regulate lipid metabolism and are used quite often in daily practice for diabetic dyslipidemia, because of its beneficial effect to reduce high TG and increase low HDL-C, which are the characteristic lipid abnormalities commonly seen in the patients with diabetes or metabolic syndrome. However, in recently published FIELD study, fenofibrate did not significantly reduce the risk of the primary outcome of coronary events in 9,795 participants with type 2 diabetes mellitus. The higher rate of starting statin therapy in patients allocated placebo might have masked a moderately larger treatment benefit. Furthermore, all the treatment trials to back up the lipid treatment guideline were conducted in Caucasians and no data about the combination therapy with fibrate and statin was published before.",[142,27],"Diabetes",[144,145,146,147,148],"CV (cardiovascular)","MI (myocardial infarction)","fenofibrate","rosuvastatin","this trial is to test the hypothesis that the addition of fenofibrate on rosuvastatin would provide a further reduction in the time","AVAILABLE","2012-12-20",{"date":152,"type":20},"2012-12-21",{"name":130,"class":47}]